Swiss National Bank
DFTX

Swiss National Bank’s Definium Therapeutics DFTX Stock Holding History

Swiss National Bank’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
221,200
+62,800
+40% +$1.55M 0.01% 995
2026
Q1 		$2.99M Hold
158,400
– – ﹤0.01% 1639
2025
Q4 		$2.12M Buy
158,400
+41,300
+35% +$511K ﹤0.01% 1842
2025
Q3 		$1.38M Buy
117,100
+2,000
+2% +$18.7K ﹤0.01% 2021
2025
Q2 		$747K Buy
115,100
+8,500
+8% +$55.9K ﹤0.01% 2242
2025
Q1 		$624K Sell
106,600
-13,300
-11% -$95.3K ﹤0.01% 2302
2024
Q4 		$835K Hold
119,900
– – ﹤0.01% 2283
2024
Q3 		$682K Buy
119,900
+9,000
+8% +$62.6K ﹤0.01% 2357
2024
Q2 		$800K Buy
+110,900
New +$970K ﹤0.01% 2271
2022
Q4 		– Sell
-56,560
Closed -$198K – 2707
2022
Q3 		$198K Hold
56,560
– – ﹤0.01% 2693
2022
Q2 		$539K Sell
56,560
-6,847
-11% -$86.6K ﹤0.01% 2595
2022
Q1 		$1.08M Buy
63,407
+11,887
+23% +$206K ﹤0.01% 2372
2021
Q4 		$1.05M Buy
51,520
+3,753
+8% +$120K ﹤0.01% 2448
2021
Q3 		$1.72M Hold
47,767
– – ﹤0.01% 2147
2021
Q2 		$2.5M Buy
+47,767
New +$2.51M ﹤0.01% 1959

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Swiss National Bank's DFTX Position: Q2 2026 in Review

Swiss National Bank increased its Definium Therapeutics (DFTX) stake by 40% in Q2 2026, buying an estimated $1.55M and bringing the position to 221,200 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #995.

Swiss National Bank first reported a position in DFTX in Q2 2021 and has held it in 15 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Swiss National Bank held 221,200 shares of Definium Therapeutics worth $10.4M as of Q2 2026.
  • Swiss National Bank bought 62,800 Definium Therapeutics shares in Q2 2026, an estimated $1.55M.
  • Definium Therapeutics made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #995 holding.
  • Swiss National Bank first reported a position in Definium Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.